Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.


30 Sep 2019


Poster Display session 3



Tumour Site

Breast Cancer


Javier Pérez-peña


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


J. Pérez-peña1, J.T. Fekete2, R. Páez3, J.A. García-Sáenz4, V. García-Barberán5, P. Pérez-Segura6, A. Pandiella7, B. Gyorffy8, A. Ocaña9, A. Manzano3

Author affiliations

  • 1 Instituto De Biología Molecular Y Celular Del Cáncer, IBSAL - Instituto de Investigación Biomédica de Salamanca, 37007 - Salamanca/ES
  • 2 2nd Department Of Paediatrics, Semmelweiss University-2nd Department of Paediatrics, 1094 - Budapest/HU
  • 3 Medical Oncology Department, Hospital Clínico San Carlos, 28040 - Madrid/ES
  • 4 Medical Oncology, Hospital Clínico San Carlos, 28040 - Madrid/ES
  • 5 Medical Oncology, Hospital Clinico Universitario San Carlos. CIBERONC Instituto de Salud Carlos III, 28040 - Madrid/ES
  • 6 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 7 Laboratorio 15, Centro de investigación del cáncer, 37007 - Salamanca/ES
  • 8 2nd Department Of Pediatrics, Semmelweis University, 1085 - Budapest/HU
  • 9 Scientific Department, GEICAM, 28703 - San Sebastian de los Reyes/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5930


Limited therapeutic options exist for the treatment of patients with triple negative breast cancer (TNBC) tumors beyond the administration of chemotherapy, and very recently, the approval of the anti PD-L1 inhibitor atezolizumab. Neoadjuvant chemotherapy is currently the standard of care treatment in the early stage disease, although reliable biomarkers of response have been scarcely described. In our study we explored whether immunologic signatures associated with inflamed tumors or hot tumors could predict outcome to neoadjuvant chemotherapy.


Publicly available transcriptomic data of more than 2,000 patients were evaluated. ROC plots were generated to assess response to therapy. Cox proportional hazards regression was computed to explore the association between gene expression and outcomes. Kaplan-Meier plots were drawn to visualize the survival differences.


Higher expression of IDO1, CXCL9, CXCL10, HLA-DRA, ISGF-3 from the IFN gamma signature, CXCL13, HLA-E, LAG3 and STAT1 from the expanded gene signature and GZMB from the CTL-level signature were associated with higher proportion without relapse in the first five years after chemotherapy in TNBC. The strongest effect was observed for STAT1 (p value =1.8e-05 and AUC 0.69, p = 2.7e-06). The best gene-set signature to predict favorable RFS was the combination of IDO1, LAG3, STAT1 and GZMB (HR 0.28 CI 0.17-0.46 p = 9.8 E-08). However, no influence on pathological complete response (pCR) was observed. Similar, no benefit was identified in any other tumor subtype: HER2 or estrogen receptor positive.


In conclusion, we describe a set of immunologic genes that predict outcome to neoadjuvant chemotherapy in TNBC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Instituto de Salud Carlos III.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.